Science CodexResearchers discover new target for human antibodies that holds key to vaccine …News-Medical.netCreating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the Uni…
Flat-Rate Subscription to In-Depth Publishing Reports on Oncology, Biosimilars …SYS-CON Media (press release)Subscription to this product provides access during one year to all existing and new reports produced by La Merie Publishing and listed in th…
Flat-Rate Subscription to In-Depth Publishing Reports on Oncology, Biosimilars …PR Newswire (press release)Subscription to this product provides access during one year to all existing and new reports produced by La Merie Publishing and listed in the …
UNC Researchers Team Up to Find New Target for Dengue Virus VaccineInfection Control TodayCreating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Caro…
Immunomedics Extends Patent Life on Therapeutic AntibodiesNASDAQMORRIS PLAINS, N.J., Feb. 26, 2014 (GLOBE NEWSWIRE) — Immunomedics, Inc.(Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based produc…
|
Immunomedics Extends Patent Life on Therapeutic Antibodies
GlobeNewswire (press release) 8,658,773, which protects a method of concentrating antibodies for subcutaneous, intramuscular or transdermal administration. The patent covers all of the Company’s therapeutic antibodies, and can also be applied to most other antibodies, permitting a … |
Immunomedics Extends Patent Life on Therapeutic AntibodiesVirtual-Strategy Magazine (press release)MORRIS PLAINS, N.J., Feb. 26, 2014 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development…
Immunomedics Extends Patent Life on Therapeutic AntibodiesWall Street JournalMORRIS PLAINS, N.J., Feb. 26, 2014 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibod…
|
Immunomedics Extends Patent Life on Therapeutic Antibodies
MarketWatch 8,658,773, which protects a method of concentrating antibodies for subcutaneous, intramuscular or transdermal administration. The patent covers all of the Company’s therapeutic antibodies, and can also be applied to most other antibodies, permitting a … Immunomedics to Present at Cowen and Company 34th Annual Health Care …Virtual-Strategy Magazine (press release) |
Idelalisib Shows Promising Activity in Heavily Pretreated iNHLOncLiveThe majority of patients (89%) had stage III or IV disease and all patients had not responded favorably to rituximab and an alkylating agent or had relapsed within 6 months of treatme…